Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression

• Príomhchruthaitheoirí: Meijia Qian (Údar), Fangjie Yan (Údar), Weihua Wang (Údar), Jiamin Du (Údar), Tao Yuan (Údar), Ruilin Wu (Údar), Chenxi Zhao (Údar), Jiao Wang (Údar), Jiabin Lu (Údar), Bo Zhang (Údar), Nengming Lin (Údar), Xin Dong (Údar), Xiaoyang Dai (Údar), Xiaowu Dong (Údar), Bo Yang (Údar), Hong Zhu (Údar), Qiaojun He (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Elsevier, 2021-12-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Cholangiocarcinoma (CCA) has emerged as an intractable cancer with scanty therapeutic regimens. The aberrant activation of Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) are reported to be common in CCA patients. However, the underpinning mechanism remains...